vs
Side-by-side financial comparison of ACADIA REALTY TRUST (AKR) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $103.0M, roughly 1.6× ACADIA REALTY TRUST). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -1.3%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 7.0%).
Acadia Realty Trust is a publicly traded real estate investment trust (REIT) that specializes in owning, operating, and redeveloping high-quality retail and mixed-use properties, primarily in dense, high-barrier-to-entry U.S. markets. Its portfolio includes neighborhood shopping centers, urban street retail assets, and community-focused mixed-use developments.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
AKR vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $103.0M | $168.4M |
| Net Profit | $139.1M | — |
| Gross Margin | — | — |
| Operating Margin | 153.9% | 50.6% |
| Net Margin | 135.1% | — |
| Revenue YoY | -1.3% | 143.7% |
| Net Profit YoY | -58.2% | — |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $103.0M | — | ||
| Q4 25 | — | $168.4M | ||
| Q3 25 | — | $87.3M | ||
| Q2 25 | — | $82.4M | ||
| Q1 25 | — | $65.0M | ||
| Q4 24 | $93.3M | $69.1M | ||
| Q3 24 | $87.7M | $51.6M | ||
| Q2 24 | $87.3M | $73.8M |
| Q1 26 | $139.1M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $-31.3M | ||
| Q2 25 | — | $-12.7M | ||
| Q1 25 | — | $-40.5M | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $12.3M | $-29.5M | ||
| Q2 24 | $1.6M | $-61.9M |
| Q1 26 | 153.9% | — | ||
| Q4 25 | — | 50.6% | ||
| Q3 25 | — | -11.4% | ||
| Q2 25 | — | 8.6% | ||
| Q1 25 | — | -34.0% | ||
| Q4 24 | 17.5% | -6.4% | ||
| Q3 24 | 19.9% | -31.0% | ||
| Q2 24 | 20.4% | 3.5% |
| Q1 26 | 135.1% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -35.9% | ||
| Q2 25 | — | -15.4% | ||
| Q1 25 | — | -62.2% | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 14.0% | -57.2% | ||
| Q2 24 | 1.8% | -83.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.32 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | $0.08 | $-0.14 | ||
| Q3 24 | $0.07 | $-0.15 | ||
| Q2 24 | $0.01 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.4M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6B | $-302.0M |
| Total Assets | $4.5B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $31.4M | — | ||
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | $16.8M | $144.8M | ||
| Q3 24 | $46.2M | $144.7M | ||
| Q2 24 | $31.9M | $189.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.7B | — |
| Q1 26 | $2.6B | — | ||
| Q4 25 | — | $-302.0M | ||
| Q3 25 | — | $-451.4M | ||
| Q2 25 | — | $-433.5M | ||
| Q1 25 | — | $-426.2M | ||
| Q4 24 | $2.1B | $-388.7M | ||
| Q3 24 | $1.9B | $-370.2M | ||
| Q2 24 | $1.8B | $-344.2M |
| Q1 26 | $4.5B | — | ||
| Q4 25 | — | $465.9M | ||
| Q3 25 | — | $364.0M | ||
| Q2 25 | — | $347.1M | ||
| Q1 25 | — | $324.0M | ||
| Q4 24 | $4.4B | $343.8M | ||
| Q3 24 | $4.3B | $314.1M | ||
| Q2 24 | $4.3B | $352.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 1.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $45.2M | ||
| Q3 25 | — | $-4.3M | ||
| Q2 25 | — | $-31.4M | ||
| Q1 25 | — | $-22.6M | ||
| Q4 24 | $140.4M | $-35.0M | ||
| Q3 24 | $44.6M | $-35.3M | ||
| Q2 24 | $32.0M | $-7.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% |
| Q1 26 | 1.7% | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 121.08× | — | ||
| Q3 24 | 3.64× | — | ||
| Q2 24 | 20.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AKR
| Rental | $98.6M | 96% |
| Other | $4.4M | 4% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
